NCI Drug Dictionary

The NCI Drug Dictionary contains technical definitions and synonyms for drugs/agents used to treat patients with cancer or conditions related to cancer. Each drug entry includes links to check for clinical trials listed in NCI's List of Cancer Clinical Trials.

carbon C 14 gilteritinib
A radioconjugate composed of gilteritinib, an inhibitor of the receptor tyrosine kinases (RTKs) FMS-related tyrosine kinase 3 (FLT3, STK1, or FLK2), AXL (UFO or JTK11) and anaplastic lymphoma kinase (ALK or CD246), labeled with the radioisotope carbon C 14, with potential use for evaluating the pharmacokinetic profile of gilteritinib. Gilteritinib binds to and inhibits both the wild-type and mutated forms of FLT3, AXL and ALK. This may result in an inhibition of FLT3, AXL, and ALK-mediated signal transduction pathways and the reduction of tumor cell proliferation in cancers that overexpress these RTKs. Labeling of gilteritinib with the radioactive tracer carbon C 14 allows for the evaluation of gilteritinib's pharmacokinetic profile, including its absorption, distribution, metabolism, and excretion (ADME). Check for active clinical trials using this agent. (NCI Thesaurus)

Synonym:[14C] ASP2215
14C-labeled gilteritinib